Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Description of studies included in analysis
Description of studies included in analysis
|
Variable |
% (No) |
|
Disease: |
|
|
Acute lymphoblastic leukaemia |
43 (65) |
|
Acute myeloblastic leukaemia |
8 (12) |
|
Hodgkin’s disease |
3 (5) |
|
Lymphoma |
10 (15) |
|
Rhabdomyosarcoma |
6 (10) |
|
Wilm’s tumour |
8 (12) |
|
Others |
22 (33) |
|
Type of treatment: |
|
|
Neo- adjuvant |
3 (4) |
|
Adjuvant |
24 (36) |
|
Induction |
7 (11) |
|
Consolidation |
7 (10) |
|
Maintenance |
39 (60) |
|
Supportive |
2 (3) |
|
Definitive* |
17 (26) |
|
Other |
1 (2) |
|
Type of intervention: |
|
|
Chemotherapy |
59 (89) |
|
Radiation therapy |
2 (3) |
|
Chemotherapy and radiation therapy |
31 (48) |
|
Others |
8 (12) |
|
Study design: |
|
|
Parallel |
97 (147) |
|
Cross over |
3 (5) |
|
No masking: |
100 (152) |
|
Expected difference in outcomes, and sample size prespecified: |
|
|
Yes |
78 (119) |
|
No |
9 (14) |
|
Missing data |
13 (19) |
|
a and b error prespecified: |
|
|
Yes |
76 (116) |
|
No |
11 (17) |
|
Missing data |
13 (19) |
|
Type of comparison: |
|
|
Active |
91 (138) |
|
Placebo or no therapy |
9 (14) |
|
Primary endpoint: |
|
|
Survival |
43 (65) |
|
Event free survival |
39 (60) |
|
Others |
18 (27) |
|
Adequate allocation concealment: |
|
|
Yes |
93 (142) |
|
No |
7 (10) |
|
Intention to treat analysis: |
|
|
Yes |
93 (142) |
|
No or unclear |
7 (10) |
|
Description of drop outs: |
|
|
Yes |
93 (141) |
|
No |
7 (11) |
*With intent to prolong survival or achieve cure.
Fig A Summary analyses according to publication status
Figure A [As supplied by authors]
|
Fig B Distribution of outcomes according to investigator’s judgment and achievement of statistical significance (126 trials involved 152 comparisons; there were missing data for 7% of studies regarding statistical significance. However, survival data from these studies were available for meta-analysis).
Figure B [As supplied by authors]
|
Fig C Children’s Oncology Group - Forest Plot of all trials
included in the analysis – Overall Survival
Fig C [As supplied by authors] Children’s Oncology Group - Forest Plot of all trials included in the analysis – Overall Survival
|
|
|
|
|
|
|
Fig D Summary analyses according to the methodological quality of trials and the choice of comparator. Notation same as in fig 2. The results were not affected by any of these methodological factors. ‡ Diff=difference; Calc=calculation.
Figure D [As supplied by authors]
|
What can you learn from this BMJ paper? Read Leanne Tite's Paper+